Paul Lizzul Sells 3,650 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 3,650 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the transaction, the insider owned 42,088 shares of the company’s stock, valued at $1,881,754.48. The trade was a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

AnaptysBio Trading Up 2.0%

Shares of NASDAQ ANAB opened at $44.67 on Friday. The stock’s 50-day moving average is $42.62 and its 200 day moving average is $31.51. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $52.47.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a share buyback plan on Friday, November 21st that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

Analysts Set New Price Targets

ANAB has been the subject of several recent research reports. Wedbush reissued an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research note on Monday, November 24th. UBS Group started coverage on AnaptysBio in a research note on Wednesday. They issued a “buy” rating and a $70.00 target price for the company. Wells Fargo & Company raised their price target on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. HC Wainwright decreased their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. Finally, Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC lifted its holdings in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the period. Bessemer Group Inc. lifted its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 1,292 shares during the period. Tower Research Capital LLC TRC lifted its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,377 shares during the period. Osaic Holdings Inc. boosted its holdings in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares in the last quarter. Finally, Covestor Ltd increased its position in AnaptysBio by 131,540.0% during the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 6,577 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.